Second-wave Protease Inhibitors: Choosing an Heir

Clinics in Liver Disease

Volumn 15, Issue 3, 2011, Pages 597-609

  Ciesek, Sandra ^a,b   von Hahn, Thomas ^a   Manns, Michael P ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

^b INSTITUTE OF INFECTION IMMUNOLOGY   (Germany)

Author keywords

Antiviral therapy; Hepatitis C virus; Protease inhibitor; Second wave

Indexed keywords

ABT 450; ACH 0141625; ACH 1625; ACH 2684; AVL 181; AVL 192; BI 201335; BMS 650032; BMS 650035; BOCEPREVIR; DANOPREVIR; EFAVIRENZ; GS 9256; IDX 320; MK 5172; NARLAPREVIR; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; RALTEGRAVIR; RITONAVIR; SERINE PROTEINASE INHIBITOR; TELAPREVIR; TMC 435350; UNCLASSIFIED DRUG; VANIPREVIR;

ANTIVIRAL ACTIVITY; DRUG MECHANISM; DRUG RESEARCH; ENZYME INHIBITION; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MOLECULAR BIOLOGY; NONHUMAN; REVIEW;

ANTIVIRAL AGENTS; CARRIER PROTEINS; HEPATITIS C; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; LACTAMS; OLIGOPEPTIDES; PROLINE; PROTEASE INHIBITORS; SULFONAMIDES; THIAZOLES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 80051920720     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.05.014     Document Type: Review

References (44)

1. von Hahn T., Steinmann E., Ciesek S., et al. Know your enemy: translating insights about the molecular biology of hepatitis C virus into novel therapeutic approaches. Expert Rev Gastroenterol Hepatol 2010, 4(1):63-79.
2. Wasley A., Alter M.J. Epidemiology of hepatitis C: geographic differences and temporal trends. Semin Liver Dis 2000, 20(1):1-16.
3. Shepard C.W., Finelli L., Alter M.J. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005, 5(9):558-567.
4. Simmonds P. Genetic diversity and evolution of hepatitis C virus-15 years on. J Gen Virol 2004, 85(Pt 11):3173-3188.
5. Ghany M.G., Strader D.B., Thomas D.L., et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009, 49(4):1335-1374.
6. Ascione A., Tartaglione T., Di Costanzo G.G. Natural history of chronic hepatitis C virus infection. Dig Liver Dis 2007, 39(SUPPL 1):S4-S7.
7. Fried M.W., Shiffman M.L., Reddy K.R., et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347(13):975-982.
8. Manns M.P., McHutchison J.G., Gordon S.C., et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358(9286):958-965.
9. Ciesek S., Manns M.P. Hepatitis in 2010: the dawn of a new era in HCV therapy. Nat Rev Gastroenterol Hepatol 2011, 8(2):69-71.
10. Bartenschlager R., Frese M., Pietschmann T. Novel insights into hepatitis C virus replication and persistence. Adv Virus Res 2004, 63:71-180.
11. Lohmann V., Körner F., Koch J., et al. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. Science 1999, 285(5424):110-113.
12. Steinmann E., Penin F., Kallis S., et al. Hepatitis C virus p7 protein is crucial for assembly and release of infectious virions. PLoS Pathog 2007, 3(7):e103.
13. Jones C.T., Murray C.L., Eastman D.K., et al. Hepatitis C virus p7 and NS2 proteins are essential for production of infectious virus. J Virol 2007, 81(16):8374-8383.
14. Hepatitis C viruses: genomes and molecular biology 2006, Horizon Bioscience, Norfolk (UK), chapter 6. C. Lin, S.L. Tan (Eds.).
15. Dustin L.B., Rice C.M. Flying under the radar: the immunobiology of hepatitis C. Annu Rev Immunol 2007, 25:71-99.
16. Manns M.P., Foster G.R., Rockstroh J.K., et al. The way forward in HCV treatment-finding the right path. Nat Rev Drug Discov 2007, 6(12):991-1000.
17. Fusco D.N., Chung R.T. New protease inhibitors for HCV - Help is on the way. J Hepatol 2011, 54(6):1087-1089.
18. Steinkuhler C., Biasiol G., Brunetti M., et al. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 1998, 37(25):8899-8905.
19. Lamarre D., Anderson P.C., Bailey M., et al. An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 2003, 426(6963):186-189.
20. McHutchison J.G., Manns M.P., Muir A.J., et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010, 362(14):1292-1303.
21. Poordad F., McCone J., Bacon B.R., et al. Boceprevir with peginterferon/ribavirin for untreated chronic hepatitis C. N Engl J Med 2011, 54:1195-1206.
22. Jacobson IM, McHutchison GJ, Dusheiko MG. Telaprevir in combination with peginterferon and ribavirin in genotype 1 HCV treatment-naive patients: final results of phase 3 ADVANCE study. 61st AASLD. Boston (MA), October 29 to November 2010.
23. Rong L., Dahari H., Ribeiro R.M., et al. Rapid emergence of protease inhibitor resistance in hepatitis C virus. Sci Transl Med 2010, 2(30):30ra32.
24. Sarrazin C., Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology 2010, 138(2):447-462.
25. Asselah T., Marcellin P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int 2011, 31(SUPPL 1):68-77.
26. Reesink H.W., Fanning G.C., Farha K.A., et al. Rapid HCV-RNA decline with once daily TMC435: a phase I study in healthy volunteers and hepatitis C patients. Gastroenterology 2010, 138(3):913-921.
27. Fried M.W., Buti M., Dore G.J., et al. Efficacy and safety of TMC 435 in combination with peginterferon-2a and ribavirin in treatment-naive genotype-1 HCV patients: 24-week interim results from the PILLAR study. Hepatology 2010, 52(SUPPL S1):LB-5.
28. Gane E.J., Rouzier R., Stedman C., et al. Antiviral activity, safety, and pharmacokinetics of danoprevir/ritonavir plus PEG-IFN alpha-2a/RBV in hepatitis C patients. J Hepatol 2011, [Epub ahead of print].
29. Terrault N., Cooper C., Balart L.A., et al. Phase II randomised, partially-blind, parallel-group study of oral danoprevir (RG7227) with PEGIFNa-2A (Pegasys) plus ribavirin in treatment-naive genotype 1 patients in treatment-naive genotype 1 patients with CHC: results of planned week 12 interim analysis of the ATLAS study. Hepatology 2010, 52(S1):335A-336A.
30. Lawitz E., Gaultier I., Poordad F., et al. 4-week virologic response and safety of ABT-450 given with low-dose ritonavir (ABT-450/r) in combination with pegylated interferon alpha-2A and ribavirin (SOC) after 3-day monotherapy in genotype 1 HCV-infected treatment-naive subjects. Hepatology 2010, 52(S1). [abstract 1885].
31. Manns M.P., Bourliere M., Benhamou Y., et al. Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection. J Hepatol 2011, 54(6):1114-1122.
32. Zeuzem S., Asselah T., Angus P.W., et al. Strong antiviral activity and safety of IFN-sparing treatment with the protease inhibitor BI201335, the HCV polymerase inhibitor BI207127 and ribavirin in patients with chronic hepatitis C. Hepatology 2010, 52(S1):223A.
33. McCauley J.A., McIntyre C.J., Rudd M.T., et al. Discovery of vaniprevir (MK-7009), a macrocyclic hepatitis C virus NS3/4a protease inhibitor. J Med Chem 2010, 53(6):2443-2463.
34. Manns M.P., Gane E.J., Rodriguez-Torres M., et al. Sustained viral response (SVR) rates in genotype 1 treatment-naive patients with chronic hepatitis C (CHC) infection treated with Vaniprevir (MK-7009), a NS3/4A protease inhibitor, in combination with pegylated interferon alfa-2A and ribavirin for 28 days. Hepatology 2010, 52(S1):361A.
35. Lok A.S., Gardiner E., Lawitz E., et al. Combination therapy with BMS-790052 and BMS-650032 alone or with pegIFN/RBV results in undetectable HCV RNA trough 12 weeks of therapy in HCV genotype 1 null responders. Hepatology 2010, 52(S1):LB-8.
36. de Bruijne J., Bergmann J.F., Reesink H.W., et al. Antiviral activity of narlaprevir combined with ritonavir and pegylated interferon in chronic hepatitis C patients. Hepatology 2010, 52(5):1590-1599.
37. Vierling J.M., Poordad F., Lawitz E., et al. Once daily narlaprevir (SCH 900518) in combination with PEGIntron/Ribavirin for treatment-naive subjects with genotype-1 CHC: interim results from NEXT-1, a phase 2A study. Hepatology 2009, 50(S4):90A.
38. Huang M., Agarwal A., Stauber K.L. ACH-1625 demonstrates sustained viral suppression in presence of uncommon drug resistant HCV variants: pharmacokinetic, pharmacodynamic and clinical virology analysis of phase I study. Hepatology 2010, 52(S1).
39. Zeuzem S., Buggisch P., Agarwal K., et al. Dual, triple, and quadruple combination treatment with a protease inhibitor (GS-9256) and a polymerase inhibitor (GS-9190) alone and in combination with ribavirin (RBV) or PEGIFN/RBV for up to 28 days in treatment naive genotype 1 HCV subjects. Hepatology 2010, 52(S1):400A-401A.
40. Brainard D.M., Petry A., Van Dyk K., et al. Safety and antiviral activity of MK-5172, a novel HCV NS3/4A protease inhibitor with potent activity against known resistance mutants, in genotype 1 and 3 HCV-infected patients. Hepatology 2010, 52(S1):182A.
41. Huang M., Podos S., Patel D., et al. ACH-2684: HCV NS3 protease inhibitor with potent activity against multiple genotypes and known resistant variants. Hepatology 2010, 52(S1):299A.
42. Reesink H., van Vliet A.A., Mühr F., et al. Antiviral activity, safety and pharmacokinetics of IDX-320, a novel macrocyclic HCV protease inhibitor, in a 3-day proof-of-concept study in patients with chronic hepatitis C. Hepatology 2010, 52(S1):224A.
43. Hagel M., Niu D., St Martin T., et al. Next generation of covalent irreversible inhibitors have superior potency across genotypes and drug resistant mutants. Hepatology 2010, 52(S1):301A.
44. Niu D., Hagel M., Qiao T., et al. AVL-181, a potent and selective irreversible HCV protease inhibitor, requires a helper amino acid in the binding microenvironment to form a covalent bond with cys-159. J Hepatol 2010, 52(S1):S297.